Summit Therapeutics Stock Down 7.0 %
Shares of Summit Therapeutics stock opened at $4.15 on Tuesday. The stock has a market cap of $835.48 million, a PE ratio of -5.12 and a beta of -0.97. Summit Therapeutics has a 12 month low of $0.66 and a 12 month high of $5.78. The business has a fifty day simple moving average of $3.19 and a 200-day simple moving average of $1.86.
Summit Therapeutics (NASDAQ:SMMT – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.14) earnings per share (EPS) for the quarter. The firm had revenue of $5.68 million for the quarter. Summit Therapeutics had a negative net margin of 1,012.41% and a negative return on equity of 104.32%.
Hedge Funds Weigh In On Summit Therapeutics
About Summit Therapeutics
Summit Therapeutics Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
- Get a free copy of the StockNews.com research report on Summit Therapeutics (SMMT)
- 3 Retail Stocks Ringing the Register in 2023
- When Will Crane Holdings Take Flight?
- Is It Time To Get Aggressive With Defense Stocks?
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.